Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.71
+0.05 (0.88%)
Jan 16, 2026, 10:13 AM EST - Market open
Solid Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts that cover Solid Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $14.7, which forecasts a 157.44% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $20.
Price Target: $14.7 (+157.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Solid Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +180.21% | Jan 14, 2026 |
| Needham | Needham | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +180.21% | Dec 4, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +145.18% | Nov 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $13 → $11 | Buy | Maintains | $13 → $11 | +92.64% | Nov 5, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +57.62% | Nov 4, 2025 |
Financial Forecast
Revenue This Year
306.00K
Revenue Next Year
n/a
from 306.00K
EPS This Year
-2.13
from -3.06
EPS Next Year
-2.08
from -2.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.2M | n/a | ||||
| Avg | 306,000 | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.93 | -1.56 | ||||
| Avg | -2.13 | -2.08 | ||||
| Low | -2.87 | -2.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.